Jan van de Winkel, Genmab CEO

Ex­clu­sive: Gen­mab's CEO touts M&A po­ten­tial as it inks first part­ner­ship out­side can­cer

Slow­ly and steadi­ly, the Dan­ish an­ti­body spe­cial­ist Gen­mab has grown in­to a $27 bil­lion mar­ket cap pow­er­house dri­ven by can­cer re­search.

Now, Gen­mab is mak­ing moves be­yond on­col­o­gy, an­nounc­ing Mon­day a mul­ti-year re­search deal with the Dutch drug­mak­er ar­genx to en­ter the mas­sive im­munol­o­gy and in­flam­ma­tion mar­ket, Gen­mab CEO Jan van de Winkel told End­points News.

The com­pa­nies will even­ly split ex­pens­es and po­ten­tial up­side and start re­search­ing two undis­closed tar­gets in can­cer and im­munol­o­gy, though it could grow to more tar­gets over time, van de Winkel said. Oth­er col­lab­o­ra­tions with BioN­Tech and J&J’s Janssen have fol­lowed such tra­jec­to­ries.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.